Literature DB >> 27498137

δ-Opioid receptors: Pivotal role in intermittent hypoxia-augmentation of cardiac parasympathetic control and plasticity.

Juan A Estrada1, Mathew A Barlow1, Darice Yoshishige1, Arthur G Williams1, H Fred Downey1, Robert T Mallet2, James L Caffrey1.   

Abstract

BACKGROUND: Intermittent hypoxia training (IHT) produces robust myocardial protection against ischemia-reperfusion induced infarction and arrhythmias. Blockade of this cardioprotection by antagonism of either β1-adrenergic or δ-opioid receptors (δ-OR) suggests autonomic and/or opioidergic adaptations.
PURPOSE: To test the hypothesis that IHT shifts cardiac autonomic balance toward greater cholinergic and opioidergic influence.
METHODS: Mongrel dogs completed 20d IHT, non-hypoxic sham training, or IHT with the δ-OR antagonist naltrindole (200μg/kgsc). The vagolytic effect of the δ-OR agonist met-enkephalin-arg-phe delivered by sinoatrial microdialysis was evaluated following IHT. Sinoatrial, atrial and left ventricular biopsies were analyzed for changes in δ-OR, the neurotrophic monosialoganglioside, GM-1, and cholinergic and adrenergic markers.
RESULTS: IHT enhanced vagal bradycardia vs. sham dogs (P<0.05), and blunted the δ2-OR mediated vagolytic effect of met-enkephalin-arg-phe. The GM-1 labeled fibers overlapped strongly with cholinergic markers, and IHT increased the intensity of both signals (P<0.05). IHT increased low and high intensity vesicular acetylcholine transporter labeling of sinoatrial nodal fibers (P<0.05) suggesting an increase in parasympathetic arborization. IHT reduced select δ-OR labeled fibers in both the atria and sinoatrial node (P<0.05) consistent with moderation of the vagolytic δ2-OR signaling described above. Furthermore, blockade of δ-OR signaling with naltrindole during IHT increased the protein content of δ-OR (atria and ventricle) and vesicular acetylcholine transporter (atria) vs. sham and untreated IHT groups. IHT also reduced the sympathetic marker, tyrosine hydroxylase in ventricle (P<0.05).
SUMMARY: IHT shifts cardiac autonomic balance in favor of parasympathetic control via adaptations in opioidergic, ganglioside, and adrenergic systems.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine; Enkephalin; GM-1; Naltrindole; Vagus

Mesh:

Substances:

Year:  2016        PMID: 27498137      PMCID: PMC5012543          DOI: 10.1016/j.autneu.2016.07.007

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  29 in total

1.  Automated measurement of nerve fiber density using line intensity scan analysis.

Authors:  Aaron Sathyanesan; Tatsuya Ogura; Weihong Lin
Journal:  J Neurosci Methods       Date:  2012-02-28       Impact factor: 2.390

2.  δ-Opioid receptor (DOR) signaling and reactive oxygen species (ROS) mediate intermittent hypoxia induced protection of canine myocardium.

Authors:  Juan A Estrada; Arthur G Williams; Jie Sun; Leticia Gonzalez; H Fred Downey; James L Caffrey; Robert T Mallet
Journal:  Basic Res Cardiol       Date:  2016-02-15       Impact factor: 17.165

3.  Effects of detergents on the redistribution of gangliosides and GPI-anchored proteins in brain tissue sections.

Authors:  Marija Heffer-Lauc; Barbara Viljetić; Katarina Vajn; Ronald L Schnaar; Gordan Lauc
Journal:  J Histochem Cytochem       Date:  2007-04-04       Impact factor: 2.479

Review 4.  The multi-tasked life of GM1 ganglioside, a true factotum of nature.

Authors:  Robert W Ledeen; Gusheng Wu
Journal:  Trends Biochem Sci       Date:  2015-05-26       Impact factor: 13.807

5.  Transient arterial occlusion raises enkephalin in the canine sinoatrial node and improves vagal bradycardia.

Authors:  K E Jackson; M Farias; A S Stanfill; J L Caffrey
Journal:  Auton Neurosci       Date:  2001-12-10       Impact factor: 3.145

6.  Determination of the localization of gangliosides using anti-ganglioside antibodies: comparison of fixation methods.

Authors:  A Schwarz; A H Futerman
Journal:  J Histochem Cytochem       Date:  1997-04       Impact factor: 2.479

7.  Intermittent hypoxic training protects canine myocardium from infarction.

Authors:  Pu Zong; Srinath Setty; Wei Sun; Rodolfo Martinez; Johnathan D Tune; Igor V Ehrenburg; Elena N Tkatchouk; Robert T Mallet; H Fred Downey
Journal:  Exp Biol Med (Maywood)       Date:  2004-09

8.  Bimodal delta-opioid receptors regulate vagal bradycardia in canine sinoatrial node.

Authors:  M Farias; K Jackson; D Yoshishige; J L Caffrey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-09       Impact factor: 4.733

9.  Two-week normobaric intermittent hypoxia exposures enhance oxyhemoglobin equilibrium and cardiac responses during hypoxemia.

Authors:  Peizhen Zhang; H Fred Downey; Shande Chen; Xiangrong Shi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-23       Impact factor: 3.619

10.  Histochemical detection of GM1 ganglioside using cholera toxin-B subunit. Evaluation of critical factors optimal for in situ detection with special emphasis to acetone pre-extraction.

Authors:  T Petr; V Smíd; J Smídová; H Hůlková; M Jirkovská; M Elleder; L Muchová; L Vitek; F Smíd
Journal:  Eur J Histochem       Date:  2010-05-12       Impact factor: 3.188

View more
  3 in total

Review 1.  Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential.

Authors:  Robert T Mallet; Eugenia B Manukhina; Steven Shea Ruelas; James L Caffrey; H Fred Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-13       Impact factor: 4.733

2.  Connexins and Atrial Fibrillation in Obstructive Sleep Apnea.

Authors:  Abdelnaby Khalyfa; David Gozal
Journal:  Curr Sleep Med Rep       Date:  2018-10-26

3.  Cardioprotective Antioxidant and Anti-Inflammatory Mechanisms Induced by Intermittent Hypobaric Hypoxia.

Authors:  Alejandro González-Candia; Alejandro A Candia; Adolfo Paz; Fuad Mobarec; Rodrigo Urbina-Varela; Andrea Del Campo; Emilio A Herrera; Rodrigo L Castillo
Journal:  Antioxidants (Basel)       Date:  2022-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.